Transcenta Holding announces a strategic collaboration and non-exclusive technology licensing agreement to advance integrated continuous flow production of biologics, enhancing global accessibility of affordable biologics.
Princeton, New Jersey, USA, and Hangzhou, China, December 29, 2025 — Transcenta Holding (06628.HK), an international clinical-stage biopharmaceutical company with fully integrated capabilities in biologics discovery, development, process development, and manufacturing, today announced that it has entered into a strategic collaboration and non-exclusive technology licensing agreement with EirGenix, Inc. (TWSE: 6589), a global biopharmaceutical development and manufacturing organization.
Under the agreement, Transcenta will grant EirGenix a non-exclusive license to its highly integrated continuous bioprocessing (HiCB) platform, which includes high-yield continuous perfusion upstream processes and integrated hybrid continuous downstream purification technologies, along with comprehensive process documentation, core process expertise, and regulatory support services. Transcenta will receive a substantial upfront payment and milestone payments, as well as future royalties related to the commercial application of the licensed technology, reflecting the shared expectation of long-term value creation through this collaboration.
The HiCB platform aims to achieve higher process efficiency, optimized process control, and product consistency, significantly reducing production costs compared to traditional fed-batch production methods, ultimately enabling more patients worldwide to access high-quality, affordable biologics.
Based on this collaboration, EirGenix will adopt Transcenta's HiCB platform to support its biologics development projects and manufacturing operations. EirGenix plans to utilize the HiCB platform to serve CDMO clients seeking highly integrated continuous flow production solutions.
"We are delighted to share the HiCB platform – Transcenta's leading achievement in highly integrated continuous flow bioprocessing – with like-minded partners to jointly drive transformation in biopharmaceutical manufacturing," said Dr. David Xue Ming Qian, Chairman and CEO of Transcenta. "By enabling partners to utilize the HiCB platform, we can collectively advance the affordability and global accessibility of innovative biopharmaceuticals. The proceeds from this and future collaborations will be reinvested into strengthening the technology platform and advancing the R&D pipeline, with a commitment to developing next-generation, best-in-class innovative therapies."
"This collaboration is a win-win initiative that combines Transcenta’s innovative capabilities in continuous biologics manufacturing with EirGenix’s proven expertise in bioprocess development and CDMO services," said Dr. Richard Li-Cheng Liu, Chairman and General Manager of EirGenix. "We hope to work together to redefine biopharmaceutical production – making it more efficient, sustainable, and cost-effective to benefit more patients globally."
About Transcenta Holding
Transcenta is a clinical-stage biopharmaceutical company with fully integrated capabilities in biologics discovery, research and development, process development, and manufacturing.
Headquartered in Suzhou, Transcenta has successfully established a global business footprint: with drug discovery, clinical, and translational research centers in Suzhou, a process and product development center as well as a drug manufacturing base in Hangzhou, and clinical development centers in China, the United States, and Europe. Transcenta is developing a diversified product pipeline comprising dozens of novel biologics, covering oncology and certain non-oncology indications such as orthopedic and renal diseases.
For more information about Transcenta, please visit the company website: www.transcenta.com or LinkedIn profile: Transcenta. If you are interested in exploring capital partnership opportunities, please contact us via ir@transcenta.com to discuss potential collaborations.
About EirGenix
EirGenix is Taiwan’s largest biologics CDMO company, providing one-stop comprehensive services ranging from cell line and process development to GMP manufacturing and analytical testing. With an internationally recognized quality system and regulatory approvals, EirGenix continuously delivers reliable biopharmaceutical manufacturing solutions to global partners.
While developing its CDMO business, EirGenix is also actively advancing its own biosimilar and ADC product pipelines, focusing on the development of antibody drugs for oncology and other disease areas. EirGenix adheres to the philosophy that “client success is our top priority” and is committed to making innovative, high-quality biologics accessible to patients worldwide.
For more information, please visit www.eirgenix.com and https://www.linkedin.com/company/eirgenix. For inquiries regarding [business development partnership opportunities], please contact: service@eirgenix.com
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
Comments (3)
to post a comment
1
1